At the time of writing, Rapport Therapeutics Inc [RAPP] stock is trading at $12.24, up 30.21%. An important factor to consider is whether the stock is rising or falling in short-term value. The RAPP shares have gain 21.91% over the last week, with a monthly amount glided 8.03%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
On July 02, 2024, Stifel initiated with a Buy rating and assigned a price target of $35 on the stock. Jefferies started tracking the stock assigning a Buy rating and suggested a price target of $35 on July 02, 2024.
For the past year, the stock price of Rapport Therapeutics Inc fluctuated between $6.43 and $29.74. Currently, Wall Street analysts expect the stock to reach $35 within the next 12 months. Rapport Therapeutics Inc [NASDAQ: RAPP] shares were valued at $12.24 at the most recent close of the market. An investor can expect a potential return of 185.95% based on the average RAPP price forecast.
Analyzing the RAPP fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.26, Equity is -0.25 and Total Capital is -0.32. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 10.03 points at the first support level, and at 7.81 for the second support level. However, for the 1st resistance point, the stock is sitting at 13.60, and for the 2nd resistance point, it is at 14.95.
Ratios To Look Out For
It is important to note that Rapport Therapeutics Inc [NASDAQ:RAPP] has a current ratio of 31.01. On the other hand, the Quick Ratio is 31.01, and the Cash Ratio is 6.14.
Transactions by insiders
Recent insider trading involved Bredt David, Chief Scientific Officer, that happened on May 15 ’25 when 8500.0 shares were sold. Chief Scientific Officer, Bredt David completed a deal on Apr 15 ’25 to sell 8500.0 shares. Meanwhile, Chief Scientific Officer Bredt David sold 8500.0 shares on Mar 14 ’25.
